Annals of Surgical Oncology

, Volume 24, Issue 12, pp 3631–3639 | Cite as

Recurrence Pattern and Lymph Node Metastasis of Adenocarcinoma at the Esophagogastric Junction

  • Yun-Suhk Suh
  • Kyung-Goo Lee
  • Seung-Young Oh
  • Seong-Ho Kong
  • Hyuk-Joon Lee
  • Woo-Ho Kim
  • Han-Kwang Yang
Gastrointestinal Oncology



The surgical approach for adenocarcinoma of the esophagogastric junction (AEJ) still is controversial despite revised tumor-node-metastasis (TNM) classification. This study aimed to evaluate the oncologic outcome of a routine transhiatal approach for AEJ in terms of recurrence and lymph node (LN) metastasis of AEJ.


Recurrence patterns and LN metastasis of a single, primary AEJ (n = 463) treated by a surgical resection using a transhiatal approach without routine complete mediastinal LN dissection or routine splenectomy were analyzed respectively. To validate current treatment for recurrence, a validation index of recurrence (ViR; overall survival/incidence of solitary recurrence factor) was developed.


The overall recurrence rate for AEJ was 20.3%, which did not differ significantly between AEJ II (20.8%; n = 125) and AEJ III (20.1%; n = 338). Mediastinal recurrence did not differ significantly among the subtypes of AEJ, irrespective of gastroesophageal junction involvement. Splenic hilar LN recurrence-free survival did not differ significantly between the gastrectomy-only group, the gastrectomy-plus-splenectomy group, and the gastrectomy plus distal pancreatectomy group. The solitary recurrence rate for the mediastinal LN was 0.7% for AEJ, and the overall median survival with that recurrence was 30.5 months. The ViR for mediastinal LN recurrence (43.6) was higher than for regional LN (20.9) or distant LN (14.6) metastasis.


In terms of LN metastasis and recurrence, a transhiatal approach without complete mediastinal LN dissection can be acceptable, and routine splenectomy is not necessary for AEJ II or AEJ III arising within the stomach.



This study was supported by Grant No. 30-2014-0090 from the Seoul National University Hospital research fund and a Grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health & Welfare, Republic of Korea (HI14C1277).

Conflict of interest

There are no conflicts of interest.

Supplementary material

10434_2017_6011_MOESM1_ESM.docx (4.5 mb)
Supplementary material 1 (DOCX 4562 kb)
10434_2017_6011_MOESM2_ESM.docx (50 kb)
Supplementary material 2 (DOCX 50 kb)
10434_2017_6011_MOESM3_ESM.docx (49 kb)
Supplementary material 3 (DOCX 49 kb)
10434_2017_6011_MOESM4_ESM.docx (5.2 mb)
Supplementary material 4 (DOCX 5392 kb)


  1. 1.
    Siewert JR, Holscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58:25–32.PubMedGoogle Scholar
  2. 2.
    Kodera Y, Yamamura Y, Shimizu Y, et al. Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert’s classification applied to 177 cases resected at a single institution. J Am Coll Surg. 1999;189:594–601.CrossRefPubMedGoogle Scholar
  3. 3.
    Siewert J, Feith M, Werner M, Stein H. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353–61.CrossRefGoogle Scholar
  4. 4.
    Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005;90:139–46; discussion 146.Google Scholar
  5. 5.
    Nakamura T, Ide H, Eguchi R, Ota M, Shimizu S, Isono K. Adenocarcinoma of the esophagogastric junction: a summary of responses to a questionnaire on adenocarcinoma of the esophagus and the esophagogastric junction in Japan. Dis Esophagus. 2002;15:219–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Edge S, Byrd D, Carducci M, Compton C. AJCC Cancer Staging Manual. Springer, New York, NY, 2009.Google Scholar
  7. 7.
    Huang Q, Shi J, Feng A, et al. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol. 2011;24:138–46.Google Scholar
  8. 8.
    Gertler R, Stein HJ, Schuster T, Rondak IC, Hofler H, Feith M. Prevalence and topography of lymph node metastases in early esophageal and gastric cancer. Ann Surg. 2014;259:96–101.CrossRefPubMedGoogle Scholar
  9. 9.
    Hasegawa S, Yoshikawa T, Aoyama T, et al. Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol. 2013;20:773–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Suh YS, Han DS, Kong SH, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255:908–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Suh YS, Kong SH, Lee HJ, Yang HK. Reply to letter: “Should Adenocarcinoma of the Esophagogastric Junction Be Classified as Esophageal Cancer? Limited to Siewert Type II, Yes.” Ann Surg. 2015;261:e67–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Suh YS, Kong SH, Lee HJ, Yang HK. Reply to the letter: “Should Adenocarcinoma of the Esophagogastric Junction Be Classified as Gastric or Esophageal Cancer, or Else as a Distinct Clinical Entity?” Ann Surg. 2016;264:e5–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254:274–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Peng J, Wang WP, Yuan Y, Hu Y, Wang Y, Chen LQ. Optimal extent of lymph node dissection for siewert type II esophagogastric junction adenocarcinoma. Ann Thorac Surg. 2015;100:263–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100:261–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (version 4). Gastric Cancer. 2017;20:1–19.CrossRefGoogle Scholar
  17. 17.
    Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19:677–83.CrossRefPubMedGoogle Scholar
  18. 18.
    Hosoda K, Yamashita K, Katada N, et al. Impact of lower mediastinal lymphadenectomy for the treatment of esophagogastric junction carcinoma. Anticancer Res. 2015;35:445–56.PubMedGoogle Scholar
  19. 19.
    Kurokawa Y, Hiki N, Yoshikawa T, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157:551–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu W, Choi G, Chung H. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93:559–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7:644–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (version 3). Gastric Cancer. 2011;14:113–23.CrossRefGoogle Scholar
  24. 24.
    Bosman FT, Carneiro F, Hruban RH, Theise ND WHO classification of tumours of the digestive system. World Health Organization, Geneva, 2010.Google Scholar
  25. 25.
    Ahn HS, Lee HJ, Hahn S, et al. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116:5592–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265:277–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246:1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mine S, Sano T, Hiki N, et al. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction. Br J Surg. 2013;100:1050–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth-edition staging primer. J Thorac Oncol. 2017;12:36–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Okabayashi T, Gotoda T, Kondo H, et al. Early carcinoma of the gastric cardia in Japan: is it different from that in the West? Cancer. 2000;89:2555–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Is adenocarcinoma of the esophagogastric junction different between Japan and Western countries? The incidence and clinicopathological features at a japanese high-volume cancer center. World J Surg. 2009;33:95–103.CrossRefPubMedGoogle Scholar
  32. 32.
    Suh YS, Yang HK. Screening and early detection of gastric cancer: East versus West. Surg Clin North Am. 2015;95:1053–66.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Yun-Suhk Suh
    • 1
  • Kyung-Goo Lee
    • 1
  • Seung-Young Oh
    • 1
  • Seong-Ho Kong
    • 1
  • Hyuk-Joon Lee
    • 1
    • 2
  • Woo-Ho Kim
    • 2
    • 3
  • Han-Kwang Yang
    • 1
    • 2
  1. 1.Department of SurgerySeoul National University College of MedicineSeoulKorea
  2. 2.Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  3. 3.Department of PathologySeoul National University College of MedicineSeoulKorea

Personalised recommendations